Telix Pharmaceuticals to acquire isotope maker ITM for $1.65bn upfront, plus up to $700m contingent

Australia's Telix Pharmaceuticals agreed to acquire isotope maker ITM Isotope Technologies for $1.65 billion upfront, plus up to $700 million contingent on ITM-11 milestones, per the companies' press release. The deal secures a major supplier of radioactive materials used in cancer treatments and adds a late-stage drug candidate.

Detected & updated continuously · Source: Nebula